FIELD: medicine.
SUBSTANCE: group of inventions relates to oncology, particularly to a combination therapy of cancer expressing PD-L1 in an individual. Method of treating cancer comprises administering to an individual a PD-1 antagonist, which is pembrolizumab, lenvatinib or a pharmaceutically acceptable salt thereof and E7386 or a pharmaceutically acceptable salt thereof. Cancer is selected from the group consisting of renal cell carcinoma (RCC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), melanoma, bladder cancer, urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), endometrial cancer and head and neck squamous cell carcinoma.
EFFECT: triple combination therapy of E7386, lenvatinib and anti-PD-1 antibody demonstrates a higher anti-tumour effect than any of the two combinations: lenvatinib + anti-PD-1 antibody or lenvatinib + E7386, or each agent when administered separately as a monotherapy.
22 cl, 12 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| DOSING REGIMEN OF A WNT INHIBITOR AND AN ANTI-PD-1 ANTIBODY MOLECULE IN A COMBINATION | 2018 |
|
RU2767533C2 |
| TIGIT ANTIBODY ADMINISTRATION REGIMEN FOR TREATING CANCER | 2019 |
|
RU2833669C2 |
| DOSING REGIMEN FOR TREATING A CSF-1R-MODULATED DISEASE | 2021 |
|
RU2835316C1 |
| COMBINED DRUG FOR TREATING KIDNEY CANCER | 2021 |
|
RU2830590C2 |
| USE OF COMBINATION OF ANTIBODY TO PD-1 AND VEGFR INHIBITOR IN PRODUCTION OF DRUG FOR TREATMENT OF MALIGNANT NEOPLASMS | 2017 |
|
RU2762746C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN TREATING CANCER | 2016 |
|
RU2834309C2 |
| METHODS OF COMBINED TREATMENT OF MALIGNANT NEOPLASMS, INCLUDING AGENTS BLOCKING CTLA-4 AND PD-1 | 2020 |
|
RU2833523C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
